|
1. Biologie
|
|
|
|
3. Prévention
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
Et Tu, Slate? Flaws with Their Questions About Gardasil [vaxopedia]
|
|
|
|
|
|
Although
the study design for Gardasil used for licensing in Europe might have
been suboptimal, although that doesn’t really come across in this Slate
piece, it seems clear that it didn’t result in safety data being missed,
and as post-licensure tests have confirmed, Gardasil is safe.
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Genetic Variation Gets More Real All the Time [In the Pipeline]
|
|
|
|
|
|
It’s
worth realizing, though, that most of the stories about personalized
medicine seem to assume that we’ll sequence someone’s genome and find
the drug or combination that will be much more likely to work. But what
this paper suggests (and what has always seemed statistically more
likely) is that it’s going to be mostly about telling people that the
drugs that work for the rest of the population won’t work for them.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12 Immunothérapies
|
|
|
Keytruda falls hard at gastric cancer hurdle [Pharmafile]
|
|
|
|
|
|
There
was a time when PD-1/L1 immunotherapy treatments could do no wrong,
blasting through indication after indication. However, the limits of the
therapies are beginning to be found with a series of surprise failures
across a number of indications.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
Regeneron pairs PD-1 latecomer with ISA’s HPV immunotherapy [FierceBiotech]
|
|
|
|
|
|
ISA101
is based on synthetic long peptides or SLPs, which are used to deliver
oncogenic antigens in the hope of stimulating an immune response to
tumors. It has already been put through its paces as a monotherapy in a
proof-of-concept study published in the New England Journal of Medicine
earlier this year, as well as in combination studies.
|
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2 Pharma
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
Brentuximab Vedotin Approved for Two Rare Lymphomas [NCI]
|
|
|
|
|
|
The
approval was based on results from a phase 3 trial called ALCANZA that
enrolled patients with mycosis fungoides or primary cutaneous anaplastic
large cell lymphoma that overexpressed the CD30 protein (CD30-positive)
who had been previously treated for their disease.
|
|
|
|
|
|
|
5.7 SABCS
|
|
|
A New PARP Drug For Breast Cancer? I'm Thrilled! [Forbes]
|
|
|
|
|
|
Pfizer
asserts that talazoparib differs from the other PARP inhibitors based
on a “highly potent dual-mechanism” of inhibition; based on preclinical
data, this agent is said to block PARP enzymatic activity and also to
trap PARP on single-strand DNA breaks.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
FDA officials to target high-risk alternative remedies [STAT]
|
|
|
|
|
|
The
Food and Drug Administration on Monday issued a new proposal for
regulating homeopathic medicines that have long been on the fringe of
mainstream medicine. The agency plans to target products that pose the
biggest safety risks, including those marketed for children or for
serious diseases.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Could Bitcoin technology help science? [Nature]
|
|
|
|
|
|
In
Pagliari’s experience, researchers exploring blockchain are becoming
wise to its problems. She notes that fellow speakers at a recent London
‘hackathon’ on using blockchains to improve clinical trials, for which
Microsoft was a partner, were careful to warn about hype.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Ms. Inappropriate Defends The Status Quo [CardioBrief]
|
|
|
|
|
|
My
own belief, which I believe is shared by many in the “less is more”
community, is that genuine improvements in the healthcare system will be
difficult to implement and impossible to pay for until we begin to rein
in the excess and abuse that Rosenbaum herself concedes in the course
of her article.
|
|
|
|
|
|